CAR T-Cells in Multiple Myeloma Are Ready for Prime Time
Open Access
- 5 November 2020
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (11), 3577
- https://doi.org/10.3390/jcm9113577
Abstract
The survival of patients with multiple myeloma (MM) has been dramatically improved in the last decade thanks to the incorporation of second-generation proteasome inhibitors (PI), immunomodulatory drugs (IMID), and, more recently, anti-CD38 monoclonal antibodies (MoAb). Nevertheless, still, a major proportion of MM patients will relapse, underscoring the need for new therapies in this disease. Moreover, survival in patients failing the current standard of care regimens (including PI, IMIDs, and anti-CD38 MoAb), which is now defined as triple-class refractory, remains dismal, and new drugs with different mechanism of action are needed. B-cell maturation antigen (BCMA)-targeted therapies and in particular chimeric antigen receptor T cell (CAR T-cell) treatment have emerged as promising platforms to overcome refractoriness to conventional drugs. In this manuscript, we review the current available data regarding CAR T-cell therapy for MM, with a special focus on target selection, clinical results, limitations, and future strategies.Keywords
This publication has 47 references indexed in Scilit:
- Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growthBritish Journal of Haematology, 2017
- A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity OptimizationMolecular Therapy, 2017
- Chimeric Antigen Receptor T Cells against CD19 for Multiple MyelomaNew England Journal of Medicine, 2015
- γ-secretase directly sheds the survival receptor BCMA from plasma cellsNature Communications, 2015
- Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myelomaScience Translational Medicine, 2015
- NKG2D ligands in tumor immunityOncogene, 2008
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple MyelomaClinical Cancer Research, 2008
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- A Soluble Form of B Cell Maturation Antigen, a Receptor for the Tumor Necrosis Factor Family Member April, Inhibits Tumor Cell GrowthThe Journal of Experimental Medicine, 2000
- The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamilyInternational Immunology, 1998